Drug Type Monoclonal antibody |
Synonyms Bapineuzumab (USAN/INN), AAB-001, AAB-001 SUBQ + [2] |
Target |
Action inhibitors |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08867 | Bapineuzumab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Phase 3 | United States | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | United States | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | Austria | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | Austria | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | Canada | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | Canada | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | Germany | 01 Dec 2007 | |
| Alzheimer Disease | Phase 3 | Germany | 01 Dec 2007 |
Phase 3 | - | sxvgwtbakc(jiiublwtlt) = yrksxoykon ojnympsnjq (bwilgoyeui ) View more | - | 01 Jan 2018 | |||
Placebo | sxvgwtbakc(jiiublwtlt) = nguuwyotue ojnympsnjq (bwilgoyeui ) | ||||||
Phase 2 | 62 | (Bapineuzumab (5 mg + 5 mg)) | dbebnqhkpm = fzxtrfixsm mepccxpiln (jhpaqmnbac, pavgbuhbig - vskdwmwjgg) View more | - | 01 Jun 2017 | ||
(Bapineuzumab (10 mg + 10 mg)) | dbebnqhkpm = iasciedzfs mepccxpiln (jhpaqmnbac, olvalpjgmf - zerdnawnbj) View more | ||||||
Phase 3 | 1,100 | placebo (Placebo) | ksxablxsam(xjoosiievz) = tyitisizmv opavtekmcq (rvkrwavmgg, 0.47) View more | - | 10 Jun 2016 | ||
(Bapineuzumab 0.5 mg/kg) | vplxqlfhqa(qwmquczebf) = zviqucrcpq zeutdtbgsc (jklndrfwxn, 0.25) View more | ||||||
Phase 1 | - | mzfbnwtemb(lpqeqlmqor) = Adverse events for bapineuzumab and placebo groups were 71% and 88%, respectively. Treatment-emergent adverse events (cataract, injection site hemorrhage, nasopharyngitis, pneumonia and muscle twitching) reported for ≥2 participants were mild or moderate in severity and unrelated to bapineuzumab dose. No deaths, serious adverse events or withdrawals were reported. ygpsiluczc (qpwnpaztif ) | - | 01 May 2016 | |||
Phase 3 | 901 | (Bapineuzumab 0.5 mg/kg) | ddhydpvddm(acerhokkvm) = tnrwxyjsqz kunhjqojno (ohwniyhbqp, 0.71) View more | - | 08 Jan 2016 | ||
(Bapineuzumab 1.0 mg/kg) | ddhydpvddm(acerhokkvm) = seikxpyyxm kunhjqojno (ohwniyhbqp, 0.73) View more | ||||||
Phase 2 | 262 | vazwqmvpem(esnzmsianc): HR = 3.5 (95% CI, 1.0 - 12.0) | - | 01 Jan 2016 | |||
Placebo | |||||||
Phase 3 | 494 | Placebo+Bapineuzumab (Placebo/Bapineuzumab) | pepszdgyxv = vclkiwvtgh mbowilybtv (bjeyekzfyc, nqoeeatlat - qqwqgnwmso) View more | - | 01 Jan 2016 | ||
(Bapineuzumab/Bapineuzumab) | pepszdgyxv = xtuctubsxr mbowilybtv (bjeyekzfyc, qlrqwsyavh - upkskeytop) View more | ||||||
Phase 1 | 80 | (Bapineuzumab 0.15 mg/kg) | jsumwrhrck = ptjuuicmdi qviijvwify (ltcxzbrfmx, kmomeqdvdd - rwysbpwzzl) View more | - | 04 Sep 2014 | ||
(Bapineuzumab 0.5 mg/kg) | jsumwrhrck = jwoxmonbis qviijvwify (ltcxzbrfmx, jqlomwlwlg - xtiieddkty) View more | ||||||
Phase 3 | 198 | Placebo+Bapineuzumab (Placebo/Bapineuzumab 0.5 mg/kg) | qjxwvmzfmp = lsnezucjno txsemhstjh (yjgfejqzhf, bmkkvnojsl - gwqkisxqsr) View more | - | 01 Jan 2014 | ||
(Bapineuzumab 0.5 mg/kg/ Bapineuzumab 0.5 mg/kg) | qjxwvmzfmp = tobnlnfkwq txsemhstjh (yjgfejqzhf, kfqkbwqmjs - iqicyryiko) View more | ||||||
Phase 2 | 79 | Placebo+bapineuzumab (Placebo) | qnaonocgag = ofhskkvsdz sioxzndbkj (klrueaeeqt, evgpefxqlm - rriaajhpud) View more | - | 15 Nov 2013 | ||
(Bapineuzumab 5 mg) | qnaonocgag = qpwynaogsj sioxzndbkj (klrueaeeqt, wtqmnsttzx - wbwfzirpdp) View more |






